| ［1］ Wendt MK, Balanis N, Carlin CR, et al. STAT3 and epithelialmesenchymal transitions in carcinomas［J］. JAKSTAT, 2014, 3(1): e28975.
［2］ Zhou N, Wu X, Yang B, et al. Stem cell characteristics of dormant cells and cisplatininduced effects on the stemness of epithelial ovarian cancer cells［J］. Mol Med Rep, 2014, 10(5): 24952504.
［3］ Niess H, Camaj P, Renner A, et al. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis［J］. Target Oncol, 2014, 10(2): 215227.
［4］ Di Stefano AB, Iovino F, Lombardo Y, et al. Survivin is regulated by interleukin4 in colon cancer stem cells［J］. J Cell Physiol, 2010, 225(2): 555561.
［5］ Volonté A, Di Tomaso T, Spinelli M, et al. Cancerinitiating cells from colorectal cancer patients escape from T cellmediated immunosurveillance in vitro through membranebound IL4［J］. J Immunol, 2014, 192(1): 523532.
［6］ Chao YL, Shepard CR, Wells A. Breast carcinoma cells reexpress Ecadherin during mesenchymal to epithelial reverting transition［J］. Mol Cancer, 2010, 9: 179.
［7］ Chao Y, Wu Q, Shepard C, et al. Hepatocyte induced reexpression of Ecadherin in breast and prostate cancer cells increases chemoresistance［J］. Clin Exp Metastasis, 2012, 29(1): 3950.
［8］ Nishikawa S, Ishii H, Haraguchi N, et al. Genotoxic therapy stimulates errorprone DNA repair in dormant hepatocellular cancer stem cells［J］. Exp Ther Med, 2012, 3(6): 959962.
［9］ Sosa MS, Bragado P, Debnath J, et al. Regulation of tumor cell dormancy by tissue microenvironments and autophagy［J］. Adv Exp Med Biol, 2013, 734: 7389.
［10］ Rogers MS, Novak K, Zurakowski D, et al. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors［J］. Mol Cancer Res, 2014, 12(5): 754764.
［11］ Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R′s of radiobiology revisited［J］. Stem Cells, 2010, 28(4): 639648.
［12］ Hu Y, Hu MM, Shi GL, et al. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable nonsmall cell lung cancer［J］. Eur J Surg Oncol, 2014, 40(9): 11361142.
［13］ Lyu T, Jia N, Wang J, et al. Expression and epigenetic regulation of angiogenesisrelated factors during dormancy and recurrent growth of ovarian carcinoma［J］. Epigenetics, 2013, 8(12): 13301346.
［14］ Zhang G, Miyake M, Lawton A, et al. Matrix metalloproteinase10 promotes tumor progression through regulation of angiogenenic and apoptotic pathways in cervical tumors［J］. BMC Cancer, 2014, 14: 310.
［15］ Straume O, Shimamura T, Lampa MJ, et al. Suppression of heat shock protein 27 induces longterm dormancy in human breast cancer［J］. Proc Natl Acad Sci USA, 2012, 109(22): 86998704.
［16］ Guichet PO, Guelfi S, Teigell M, et al. Notch1 stimulation induces a vascularization switch with pericytelike cell differentiation of glioblastoma stem cells［J］. Stem Cells, 2015, 33(1): 2134.
［17］ Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phaseselimination, equilibrium and escape［J］. Curr Opin Immunol, 2014, 27: 1625.
［18］ Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled tria［J］. Lancet, 2010, 376(9742): 687697.
［19］ Perez EA, Romond EH, Suman VJ, et al. Fouryear followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B31［J］. J Clin Oncol, 2011, 29(25): 33663373.
［20］ Primrose J, Falk S, FinchJones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomized controlled trial［J］. Lancet Oncol, 2014, 15(6): 601611.
［21］ Wefers C, Lamberrt LJ, Torensma R, et al. Cellular immunotherapy in ovarian cancer: targeting the stem of recurrence［J］. Gynecol Oncol, 2015, 137(2): 335342.
［22］ Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer［J］. Nat Rev Immunol, 2012, 12(4): 239252.
［23］ Sun Y, Peng S, Qiu J, et al. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ Tcell immune responses and antitumor effects against cervicovaginal tumors［J］. Gene Ther, 2015, In press.
［24］ Vasaturo A, Di Blasio S, Peeters DG, et al. Clinical implications of coinhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go［J］. Front Immunol, 2013, 4: 417.
［25］ Bragado P, Sosa MS, Keely P, et al. Microenvironments dictating tumor cell dormancy［J］. Recent Results Cancer Res, 2012, 195: 2539.
［26］ Yumoto K, Eber MR, Berry JE, et al. Molecular pathways: niches in metastatic dormancy［J］. Clin Cancer Res, 2014, 20(13): 33843389.
［27］ Pulukuri SM, Gorantla B, Dasari VR, et al. Epigenetic upregulation of urokinase plasminogen activator promotes the ropism of mesenchymal stem cells for tumor cells［J］. Mol Cancer Res, 2010, 8(8): 10741083.
［28］ Ferraris GM, Schulte C, Buttiglione V, et al. The interaction between uPAR and vitronectin triggers ligandindependent andhesion signaling by integrins［J］. EMBO J, 2014, 33(21): 24582472.
［29］ André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy?［J］. Nat Rev Clin Oncol, 2014, 11(7): 413431. |
